ATLANTA, Sept. 14, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will present virtually at the upcoming Gilmartin Group Emerging Growth Company Showcase on Thursday, September 21, 2023. The Company's presentation is scheduled to begin at 11:00 a.m. ET.
A live webcast of the presentation will be accessible through Artivion's website, www.artivion.com, on the Investors page. An archived copy of the webcast will be available for 90 days on the same website.
About Artivion, Inc.
Headquartered in suburban Atlanta, Georgia, Artivion, Inc. is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.artivion.com.
Artivion D. Ashley Lee Executive Vice President & Chief Financial Officer Phone: 770-419-3355 | Gilmartin Group LLC Brian Johnston / Lynn Lewis Phone: 332-895-3222 This email address is being protected from spambots. You need JavaScript enabled to view it. |

| Last Trade: | US$46.31 |
| Daily Change: | -0.58 -1.24 |
| Daily Volume: | 211,358 |
| Market Cap: | US$2.190B |
November 06, 2025 November 06, 2025 August 07, 2025 | |

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load